These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25379431)

  • 1. Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study.
    Nagashima M; Monden Y; Dan I; Dan H; Tsuzuki D; Mizutani T; Kyutoku Y; Gunji Y; Hirano D; Taniguchi T; Shimoizumi H; Momoi MY; Watanabe E; Yamagata T
    Neuroimage Clin; 2014; 6():192-201. PubMed ID: 25379431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Right prefrontal activation as a neuro-functional biomarker for monitoring acute effects of methylphenidate in ADHD children: An fNIRS study.
    Monden Y; Dan H; Nagashima M; Dan I; Tsuzuki D; Kyutoku Y; Gunji Y; Yamagata T; Watanabe E; Momoi MY
    Neuroimage Clin; 2012; 1(1):131-40. PubMed ID: 24179746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.
    Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer MJ; Simmons A; Rubia K
    Cereb Cortex; 2014 Jan; 24(1):174-85. PubMed ID: 23048018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
    Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
    Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacological effect of methylphenidate on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy.
    Nagashima M; Monden Y; Dan I; Dan H; Tsuzuki D; Mizutani T; Kyutoku Y; Gunji Y; Momoi MY; Watanabe E; Yamagata T
    Neurophotonics; 2014 Jul; 1(1):015001. PubMed ID: 26157971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropharmacological effect of atomoxetine on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy.
    Nagashima M; Monden Y; Dan I; Dan H; Mizutani T; Tsuzuki D; Kyutoku Y; Gunji Y; Hirano D; Taniguchi T; Shimoizumi H; Momoi MY; Yamagata T; Watanabe E
    Neurophotonics; 2014 Oct; 1(2):025007. PubMed ID: 26157979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
    Smith A; Cubillo A; Barrett N; Giampietro V; Simmons A; Brammer M; Rubia K
    Biol Psychiatry; 2013 Oct; 74(8):615-22. PubMed ID: 23731741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.
    de Jong CG; Van De Voorde S; Roeyers H; Raymaekers R; Allen AJ; Knijff S; Verhelst H; Temmink AH; Smit LM; Rodriques-Pereira R; Vandenberghe D; van Welsen I; ter Schuren L; Al-Hakim M; Amin A; Vlasveld L; Oosterlaan J; Sergeant JA
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):699-707. PubMed ID: 20035588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
    Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
    J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualizing Neuropharmacological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder Using Functional Near-Infrared Spectroscopy.
    Ikeda T; Inoue A; Tanaka D; Hashimoto T; Sutoko S; Tokuda T; Kyutoku Y; Maki A; Yamagata T; Dan I; Monden Y
    Front Neuroergon; 2021; 2():657657. PubMed ID: 38235230
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinically-oriented monitoring of acute effects of methylphenidate on cerebral hemodynamics in ADHD children using fNIRS.
    Monden Y; Dan H; Nagashima M; Dan I; Kyutoku Y; Okamoto M; Yamagata T; Momoi MY; Watanabe E
    Clin Neurophysiol; 2012 Jun; 123(6):1147-57. PubMed ID: 22088661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved prefrontal activity in AD/HD children treated with atomoxetine: a NIRS study.
    Araki A; Ikegami M; Okayama A; Matsumoto N; Takahashi S; Azuma H; Takahashi M
    Brain Dev; 2015 Jan; 37(1):76-87. PubMed ID: 24767548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
    Ota T; Iida J; Nakanishi Y; Sawada S; Matsuura H; Yamamuro K; Ueda S; Uratani M; Kishimoto N; Negoro H; Kishimoto T
    Psychiatry Clin Neurosci; 2015 Mar; 69(3):161-70. PubMed ID: 25359429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual classification of ADHD children by right prefrontal hemodynamic responses during a go/no-go task as assessed by fNIRS.
    Monden Y; Dan I; Nagashima M; Dan H; Uga M; Ikeda T; Tsuzuki D; Kyutoku Y; Gunji Y; Hirano D; Taniguchi T; Shimoizumi H; Watanabe E; Yamagata T
    Neuroimage Clin; 2015; 9():1-12. PubMed ID: 26266096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.
    Arnold LE; Aman MG; Cook AM; Witwer AN; Hall KL; Thompson S; Ramadan Y
    J Am Acad Child Adolesc Psychiatry; 2006 Oct; 45(10):1196-1205. PubMed ID: 17003665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine transporter genotype influences the physiological response to medication in ADHD.
    Gilbert DL; Wang Z; Sallee FR; Ridel KR; Merhar S; Zhang J; Lipps TD; White C; Badreldin N; Wassermann EM
    Brain; 2006 Aug; 129(Pt 8):2038-46. PubMed ID: 16760197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.